Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A multi-agent chemotherapy regimen combining the microtubule-interfering agents estramustine and vinorelbine, investigated primarily for androgen-independent/hormone-refractory metastatic prostate cancer. Estramustine is an estradiol–nitrogen mustard conjugate that disrupts microtubule dynamics and binds microtubule-associated proteins, exerting antimitotic effects; vinorelbine is a semisynthetic Vinca alkaloid that inhibits microtubule polymerization, leading to mitotic arrest and apoptosis. Phase I/II studies reported the combination to be generally tolerable with modest activity, including prostate-specific antigen (PSA) declines in a subset of patients, using both oral and intravenous vinorelbine schedules alongside oral estramustine.[2][1]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on estramustine + vinorelbine.